Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Channel-Free Microfluidic Technology for Molecular Testing Developed

Published: Saturday, February 08, 2014
Last Updated: Thursday, February 27, 2014
Bookmark and Share
The Smart FilmCARD would be the first microfluidic device in the diagnostics industry with no channels included in its design.

Rheonix, Inc. has created a channel-free microfluidic device, the Rheonix Smart FilmCARD™. This breakthrough will significantly decrease the research, development and production costs of microfluidic solutions and allow sophisticated diagnostic tests to become more widely available. The Smart FilmCARD is capable of complex fluid manipulations with potential applications in research laboratories, genetic sequencing sample preparations and in vitro diagnostic (IVD) assays. 

The Smart FilmCARD is a groundbreaking evolution of Rheonix’s existing core technology, the Chemistry and Reagent Device (CARD®). The CARD runs samples through a fully integrated molecular assay without user intervention based upon Rheonix’s novel solvent lamination capabilities. Compared with the CARD technology, the Smart FilmCARD uses the deformed gasket wall to replace channels for fluidic network formation. The channel-free design permits controlled movement of fluids anywhere on the Smart FilmCARD while virtually eliminating dead-volume losses typical of channeled devices. Without channels, reagents can be packaged and stored easily on the device to allow more varied applications than are currently possible in the life sciences tools and IVD markets. 

“The capability to reliably package micro-liter volumes of reagents into a device and pump those reagents in a manner that is not limited by predefined fluid pathways opens Rheonix to diagnostic applications not previously envisioned, or possible,” said Peng Zhou, Ph.D., Rheonix chief scientific officer. “For the first time, we will be able to work with researchers and developers to design a device with the cost structure and function that enables subsidy-free adoption of advanced molecular technologies to facilitate widespread diagnosis of diseases such as drug-resistant tuberculosis, malaria, dengue fever, Chagas disease and other human afflictions that cause serious illness and death throughout the world.” 

The Smart FilmCARD enables Rheonix to address diverse market requirements that are too difficult to perform with existing systems, such as automated next-generation sequencing library sample preparation, low-cost infectious disease panel testing and point-of-care applications. It also enables Rheonix to serve markets requiring small-volume reagent management, onboard reagents and simpler testing procedures while dramatically lowering the complexity of manufacturing molecular devices. 

“Simply put, we see applications for this platform across the full spectrum of molecular analysis applications. This elegantly simple approach to fluidic handling has the ability to address market needs around the globe with functional utility in applications as diverse as next-generation sequencing preparations and point-of-care molecular diagnostics testing,” said Tony Eisenhut, Rheonix president. 

The Smart FilmCARD development efforts will continue within the newly formed Rheonix Innovation Center under the direction of Peng Zhou. Zhou holds 14 U.S. patents. “For a researcher, there is nothing more exciting than being given a blank canvas and the tools to create solutions for pressing problems. The Smart FilmCARD is this canvas, and we will explore a variety of applications free from constraints due to cost-of-goods-sold limitations,” Zhou said.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rheonix Raises $28.6 Million to Further Expand MDx Efforts
Company further expand the commercialization efforts of molecular testing platforms.
Friday, October 23, 2015
Rheonix Inc. Raises $28.6 Million
Rheonix Inc.raised $28.6 million to further expand the company’s commercialization efforts for its breakthrough molecular testing platforms, the Encompass MDx® and Encompass Optimum™.
Thursday, October 22, 2015
Rheonix Receives Patent for Molecular Diagnostic Testing Device
The company has been granted patent 9,132,398, “Integrated Microfluidic Device and Methods,” for the Rheonix CARD® cartridge, which enables assays to be performed on the company’s EncompassMDx® and Encompass Optimum™ instruments.
Wednesday, September 16, 2015
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos